Please login to the form below

Not currently logged in
Email:
Password:

Roy Baynes joins Gilead’s oncology division

Former Amgen man to become senior VP, oncology therapeutics at the US biopharma company

Roy Baynes - GileadDr Roy Baynes has been appointed senior VP, oncology therapeutics at US biopharmaceutical company Gilead.

His appointment comes after a 10-year spell at Amgen, where he served as VP of global development and therapeutic area head of haematology and oncology.

“Roy has an extensive background in clinical practice, academic research and in cancer drug development,” said Dr Norbert Bischofberger, executive VP, R&D and chief scientific officer.

“Under his leadership, we are well positioned to advance our growing number of pipeline programmes targeted at both haematological malignancies and solid tumours.”

Baynes will report to Bischofberger as part of his new role leading Gilead's programme in oncology.

Baynes added: “Cancer research is an incredibly challenging and evolving field, but one with great opportunity and I look forward to working closely with the internal team and external collaborators as we seek to develop novel cancer therapies that address significant unmet medical needs.”

Prior to his role at Amgen, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit.

He was also a professor of medicine, professor of oncology and director of the bone marrow transplant programme during his time at Wayne State.

20th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics